Compare MAXN & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAXN | BTAI |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 43.7M |
| IPO Year | N/A | 2018 |
| Metric | MAXN | BTAI |
|---|---|---|
| Price | $2.96 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 47.4K | ★ 644.4K |
| Earning Date | 03-06-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,414,000.00 | $752,000.00 |
| Revenue This Year | $100.37 | N/A |
| Revenue Next Year | $24.61 | $265.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.49 | $1.17 |
| 52 Week High | $6.76 | $8.08 |
| Indicator | MAXN | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.58 | 46.07 |
| Support Level | $2.70 | $1.85 |
| Resistance Level | $3.17 | $2.08 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 60.14 | 42.45 |
Maxeon Solar Technologies Ltd is engaged in the manufacturing and marketing of premium solar technology. It owns and operates solar cell and panel manufacturing facilities located in Malaysia, Mexico, and the Philippines. The company's primary products are the Maxeon line of interdigitated back contact (IBC) solar cells and panels, and the Performance line (formerly, P-Series) of shingled solar cells and panels. the Maxeon line of solar panels are the highest-efficiency solar panels on the market with an aesthetically pleasing design, and the Performance line of solar panels offers a high-value and cost-effective solution. It is targeted at residential and small-scale commercial customers across the globe. The company derives its revenue from the United States, Italy, and Rest of world.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.